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ABSTRACT 
Introduction: To evaluate the clinical characteristics of DLB subjects who died within 1 
year of assessment compared to those who survived and investigate their patterns of in 
vivo regional thalamic atrophy using structural MRI.  
Methods: Seventy subjects (35 DLB, 35 aged controls) underwent 3 Tesla T1-weighted 
MR scanning as well as clinical and cognitive assessments, including a computerised 
assessment of attention. All subjects were contacted after 12 months for reassessment.  
For both hemispheres, using FSL FIRST, the thalamus was automatically segmented 
followed by inter-subject vertex-wise analyses involving group comparisons and 
behavioural correlates. 
Results:  There was significant bilateral atrophy in the ventral-dorsal and pulvinar regions 
in DLB relative to controls (pcorrected < 0.05). The DLB group was then re-categorised 
based on 12-month mortality data: DLB-a
 
(n=25) and DLB-d (n=9) (a=alive, d=death 
within 12 months of study assessment). Compared to controls, significant attentional 
dysfunction and bilateral atrophy of the pulvinar, ventral and dorsal nuclei were observed 
in DLB-d
 
(pcorrected < 0.05), whereas in DLB-a, atrophy was far less extensive.  
Conclusions:  Distinct patterns of thalamic atrophy occur in DLB that may relate to the 
attentional dysfunction and cognitive fluctuations that characterise this disorder. Relative 
to controls, the extent of attentional impairment and pattern of thalamic degeneration 
differ in those patients who died within 12 months of assessment, despite having an 
otherwise similar level of dementia severity.  These findings may provide insight into the 
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neurobiological changes underpinning important clinical characteristics and disease 
heterogeneity. 
1. Introduction 
 
Dementia with Lewy bodies (DLB) is a common form of dementia in late life. It is 
associated with higher morbidity, mortality and a poorer quality of life when compared to 
Alzheimer’s disease (AD) [1-3]. It is a heterogeneous condition with a proportion of 
people deteriorating very rapidly until death. However, we do not have a good 
understanding of the pathophysiological mechanisms underpinning the differing clinical 
features and the potential influence that they may have on disease course and patient 
outcomes. A shorter duration of illness has been reported in DLB compared to AD 
although the reasons were not clear and the difference remained significant even when 
factors such as age, gender and vascular risk factors were controlled for [1, 4].  
 
Attentional dysfunction is prominent in DLB and related to cognitive fluctuations, one of 
the core clinical features of the disease [5]. Interestingly, a case series of six patients with 
DLB and rapid progression had prominent attentional deficits at presentation [6]. The 
neurobiological correlate of attentional function in DLB is unclear, although increased 
cognitive fluctuations have been reported to be associated with increased thalamic 
perfusion in DLB [7]. 
 
The thalamus is a key area in maintaining consciousness and is an area vulnerable to 
Lewy body related pathology [8].  It is an important deep brain structure, key to many 
sensory, motor and cognitive systems where it has received much interest in the cognitive 
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neurosciences [9] including examination of thalamic structure using magnetic resonance 
imaging (MRI). Thalamic volume and shape changes have been reported in AD [10-13], 
while variations in thalamic diffusion and perfusion have been shown in DLB [14-16].  
 
We aimed to evaluate attentional function and patterns of in vivo regional atrophy of the 
thalamus using structural MRI in DLB, comparing the characteristics of DLB subjects 
who died within 1 year of assessment to those who survived. We hypothesised that those 
DLB subjects who died within a year would have greater attentional impairment (but not 
global cognitive impairment) at baseline as well as greater thalamic atrophy than those 
who survived. As an exploratory analysis, the correlation between attentional function 
and thalamic shape change was also examined, hypothesising that greater attentional 
impairment would relate to atrophy in the posterior region (pulvinar) of the thalamus. 
 
2. Methods 
2.1. Subjects, assessments and diagnosis 
Thirty five individuals over the age of 60 with probable DLB [5, 17] were recruited from 
a community dwelling population of patients referred to local Old Age Psychiatry, 
Geriatric Medicine or Neurology Services. Thirty-five similar aged healthy control 
subjects were also recruited from relatives and friends of subjects with dementia or 
volunteered via advertisements in local community newsletters. The research was 
approved by the local ethics committee. All subjects or, where appropriate, their nearest 
relative, provided written informed consent. All subjects underwent clinical and 
neuropsychological evaluations and the clinical diagnosis of probable DLB was assigned 
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by independent clinical raters as previously described [18]. This included assessment for 
Rapid Eye Movement (REM) sleep behaviour disorder using the International 
Classification of Sleep Disorders-II diagnostic criteria B [19]. Assessments included the 
Cambridge Cognitive Examination (CAMCOG) incorporating the Mini-Mental State 
Examination (MMSE) [20], the Unified Parkinson’s Disease Rating Scale Part III 
(UPDRS-III) [21], Bristol ADL and Neuropsychiatric inventory. Attention was assessed 
with the Cognitive Drug Research (CDR) computerised assessment system and included 
measures of Simple Reaction Time (SRT), Choice Reaction Time (CRT) and Digit 
Vigilance (DigVig) [22]. 
 
2.2. MRI data acquisition 
Subjects underwent T1 weighted MR scanning on a 3T MRI system using an 8 channel 
head coil (Intera Achieva scanner, Philips Medical Systems, Eindhoven, Netherlands) 
within 2 months of the study assessment, as previously described [18]. The sequence was 
a standard T1 weighted volumetric sequence covering the whole brain (3D MPRAGE, 
sagittal acquisition, 1 mm isotropic resolution and matrix size of 240 (anterior-posterior) 
x 240 (superior-inferior) x 180 (right-left); repetition time (TR) = 9.6ms; echo time (TE) 
= 4.6ms; flip angle = 8o; SENSE factor = 2). The acquired volume was angulated such 
that the axial slice orientation was standardised to align with the AC-PC line. 
 
2.3. Thalamic segmentation using FIRST  
Estimates of thalamic volumes were conducted using the FSL (FMRIB Software Library, 
ver. 5.06, http://www.fmrib.ox.ac.uk/fsl) tool FIRST. The method used shape and 
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intensity models of the thalamus, constructed from manually segmented T1 datasets 
(n=336), generating surface meshes constrained to preserve vertex number and 
correspondence. Using these learned models, FIRST then searches through linear 
combinations of shape variations to obtain the most probable surface/shape given the 
observed set of voxel intensities for the thalamus for each and every subject. Surfaces 
were then aligned to MNI125 space to enable intersubject vertex-wise analyses [23]. 
 
2.4. Statistical Analysis 
For demographic and clinical data, the Statistical Package for Social Sciences software 
(SPSS ver. 19.0.0.1, http://www-01.ibm.com/software/analytics/spss/) was used for 
statistical evaluation. Continuous variables were examined for normality using the 
Shapiro-Wilk test and visual inspection of variable histograms and assessed where 
appropriate using parametric (t-tests) and non-parametric (Mann-Whitney U) tests. For 
categorical data, χ2 tests were applied. A p-value of ≤ 0.05 was considered significant.   
 
Vertex shape analysis was performed using the FSL script first_utils in order to assess 
group effects and behavioural correlates on a per-vertex basis. Regional changes in the 
vertices between groups were conducted using a two-sample unpaired t-test with age and 
total intracranial volume (TIV) as confounding variables. Exploratory multiple regression 
analysis was used to investigate the relationship between regional changes and behaviour 
in DLB with age as confounding covariate. Statistical inference was evaluated using the 
program randomise with 5000 permutations generating the appropriate statistic images.  
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Results were family-wise error corrected (p ≤ 0.05) using the threshold free cluster 
enhancement (TFCE) method [24]. 
3. Results 
3.1. Subjects 
Table 1 shows demographic and group characteristics of healthy controls and patients 
with DLB. Groups were of similar age and there were more men in the DLB than control 
group. As expected, those with DLB had greater global cognitive and attentional 
impairment and higher UPDRS III scores than healthy controls.   
 
3.2. Thalamic atrophy in DLB relative to healthy subjects 
Significant bilateral atrophy in the ventral-dorsal and pulvinar regions of the thalamus 
was observed in DLB relative to controls (Fig. 1A, orange regions). Table 2, depicts peak 
significance and MNI coordinates of results. 
 
3.3. Attentional impairment as an indicator of disease vulnerability  
The DLB group was then re-categorised based on 12-month survival data: DLB-a
 
and 
DLB-d (a=alive, d=death within 12 months of study assessment) (Table 3). Groups were 
comparable in age and estimated disease duration. Measures of global cognition, motor 
parkinsonism, neuropsychiatric features and normalised total hippocampal volumes 
(obtained from a previous imaging study of dementia [25]) were also similar. 
Furthermore, prescription of cholinesterase inhibitors, number or prescribed medications 
and history of vascular comorbid conditions were not significantly different between 
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groups. Attention was more impaired in the DLB-d group and reached statistical 
significance for the vigilance task. 
 
3.4. Thalamic atrophy in DLB as an indicator of disease vulnerability 
Compared to controls, significant bilateral atrophy of the pulvinar, ventral and dorsal 
regions were observed in DLB-d
 
(Fig. 1C, orange areas), whereas in DLB-a,
 
atrophy was 
much less extensive, affecting the bilateral dorsal-lateral and right ventral lateral nuclei 
regions (Fig. 1B). Patterns did not significantly differ between DLB-d
 
and
 
DLB-a 
(pcorrected > 0.05). 
 
3.5. Attentional impairment correlates with thalamic shape change in DLB 
Exploratory linear regression analysis revealed that atrophy in the region of the left 
pulvinar and ventral lateral nucleus was associated with impaired attentional function in 
DLB (PTFCE-uncorrected < 0.05). 
 
4. Discussion 
The main study findings included: (1) 26% of DLB subjects died within 12 months of 
assessment; (2) this group (DLB-d) had greater attentional but not global cognitive 
impairment; (3) DLB was characterised by thalamic atrophy in the ventral, dorsal and 
pulvinar regions of the thalamus and (4) relative to controls, thalamic degeneration was 
more extensive in the DLB-d group.  
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DLB is a heterogeneous condition. There are substantial differences between people with 
DLB in their disease course, response to treatment and also vulnerability to infection and 
neuroleptic medications. However, the reasons for these differences are unclear and there 
are currently no clinically defined sub-groups. A shorter duration of illness has been 
reported in DLB compared to AD [1]. Furthermore, a more rapidly progressive DLB sub-
type has been previously suspected; however, features that may predict this have not been 
examined.   
 
Attentional impairment is more common in DLB than AD, and is associated with 
cognitive fluctuation, one of the core clinical features of the disease [5]. Using the CDR 
computerised attentional battery, we found that the DLB-d group had more impaired 
attention which reached statistical significance for the digit vigilance task; whereas other 
clinical measures including motor function, neuropsychiatric symptoms and vascular risk 
factors were similar. In an exploratory logistic regression analysis that included age and 
gender, digit vigilance standard deviation was found to be a significant predictor of 
mortality (p<0.05). This suggests the possibility of a more vulnerable DLB sub-group 
although conclusions were somewhat limited by the small sample size.  
 
The neurobiological correlate of attentional dysfunction in DLB is unclear. However, the 
thalamus is a key area in maintaining consciousness and is an area vulnerable to Lewy 
body related pathology. The association observed between fluctuation and increased 
thalamic perfusion in DLB highlights its potential importance in the underlying 
pathological process [7]. Furthermore, one model of attentional function suggested that 
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the alerting task (vigilance) involved the thalamic areas [26, 27]. Thalamic atrophy in 
DLB included the internal medullary lamina region, part of the thalamus which is 
implicated in the maintenance of attention. It contains key intralaminar nuclei including 
the centromedian-parafasicular complex (CMPf) which, with the nucleus reticularis, 
forms part of the reticulo-thalamo-cortical activating system, highlighting their 
importance in consciousness. Interestingly, a pathological study in Parkinson’s disease 
(PD), a disease closely related to DLB, reported selective neuronal loss in the CMPf 
complex [28]. An MRI study of the thalamus in 18 PD subjects reported that whilst there 
were no differences in volume compared to healthy control subjects, there was bilateral 
shape change along the dorsal surface, which possibly represented degeneration of the 
CMPf complex. The pulvinar, located in the posterior thalamic region is thought to be 
involved in sensory attentional orienting with projections to the posterior parietal 
structures. We found atrophy in this region with relative sparing of medial aspects of the 
thalamus, which was in contrast to dorsal-medial thalamic shape change reported in AD 
[12]. Moreover, attention (choice reaction time standard deviation) correlated with 
regional change in the left posterior and dorsal-lateral thalamic regions suggesting that 
these areas may be important in understanding the neurobiological change underpinning 
attentional dysfunction and cognitive fluctuation in DLB. 
 
Further analysis of thalamic shape change revealed that the DLB-d group had more 
extensive regional atrophy than the DLB-a group in comparison to healthy controls. 
Areas affected included posterior, ventral and dorsal regions and very little change was 
observed in the DLB-a group. Differences between these subgroups did not reach 
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statistical significance and may have been due to the unbalanced and relatively small 
samples. However, the more extensive thalamic atrophy observed may be an important 
marker of disease severity in DLB and warrants further investigation. It is not clear 
whether attentional impairment in DLB may contribute to rapid decline and mortality 
through, for example, fall-related injuries or whether it heralds an important DLB sub-
type, vulnerable to rapid progression or possibly neuroleptic sensitivity reactions, 
characterised by greater thalamic degeneration. A large prospective longitudinal study is 
needed to address this. 
 
Study strengths include: a well characterised DLB group, 3T MRI dataset and validated 
imaging methodologies. The cause of death for the DLB-d group is not known. However, 
DLB groups were similar in terms of their global cognition, duration of illness, vascular 
risk factors and overall disease burden at initial assessment. The reliance on clinical 
diagnosis was a limitation, as with all ante-mortem imaging studies as well as the 
relatively small sample characterising the DLB-d group. However, methods of diagnosis 
were robust and clinical scales used are well validated, where these methods has been 
shown to have high specificity in autopsy confirmation studies [29].  
 
This was the first study to identify regional patterns of thalamic atrophy in DLB 
compared to healthy subjects. Such patterns in DLB may also relate to the attentional 
dysfunction and cognitive fluctuations that characterise this disorder. The extent and 
pattern of degeneration appear to differ in those patients who died within 12 months of 
assessment, despite having an otherwise similar level of dementia severity.  These 
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findings may provide insight into the neurobiological changes underpinning important 
clinical characteristics and disease heterogeneity in DLB. 
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Table 1 Demographic and group characteristics. 
 
 
 
Table 2 Peak significance of surface results. Table depicts voxel significance (PTFCE-corr), 
extent (k) and MNI coordinates.  
 
 
 
Table 3 Demographic and group characteristics of DLB subgroups based on survival 
data. 
 
 
 
Fig. 1. Significant regional atrophy of the thalamus (orange areas) in DLB (A), DLB-a 
(B) and DLB-d (C) relative to healthy older controls. (L=Left, R=Right, A=Anterior, 
P=Posterior). 
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Table 1 Demographic and group characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values expressed as Mean ± 1 SD.  
 
MMSE = Mini mental state examination, CAMCOG = Cambridge cognitive examination, NPI = 
Neuropsychiatric inventory, RBD= REM sleep Behaviour disorder, UPDRS III = Unified Parkinson’s disease 
rating scale (section III), SRT = Simple reaction time, CRT = Choice reaction time, Digit_Vig = Digit 
Vigilance. 
 
†
 Performed on transformed data. 
Bold text denotes statistical significance. 
 
 
 
 
Controls 
 
DLB
 
 
Statistic, p value 
    
n 35 35  
Gender (m: f) 20: 15 27: 8 χ2 = 3.2, 0.08 
Age (yrs) 76.7 ± 5.2 78.4 ± 6.9 t68 = 1.1, 0.3 
MMSE 29.1 ± 1.0 20.3 ± 5.3 t68 = 9.7, <0.001 
CAMCOG 97.3 ± 3.8 67.7 ± 15.3 t68 = 11.2, <0.001 
   
 
NPI total Na 21.5 ± 17.1  
UPDRS III 2.0 ± 1.9 26.0 ± 10.7 U70 = 1225.0, <0.001 
   
 
SRTmean 319.5 ± 71.5 692.3 ± 592.1 t68 = 7.0, <0.001† 
SRTSD 64.4 ± 24.2 308.8 ± 569.3 t68 = 4.8, <0.001† 
CRTmean 516.7 ± 92.4 1104.5 ± 737.9 t68 = 8.8, <0.001† 
CRTSD 98.8 ± 29.4 477.1 ± 665.3 t68 = 7.9, <0.001† 
Digit_Vigmean 424.3 ± 50.5 608.3 ± 109.9 t68 = 9.3, <0.001† 
Digit_VigSD 62.0 ± 20.4 133.3 ± 47.5 t68 = 8.6, <0.001† 
   
 
ChI use (y: n) Na 30: 5  
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Table 2 Peak significance of surface results. Table depicts voxel significance (PTFCE-corr), 
extent (k) and MNI coordinates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Voxel-level 
(PTFCE-corr) 
Extent 
(k) 
MNI Coordinates  
(x,y,z) (mm) 
    
    
Controls vs. DLB 0.002 1842 -6, -18, -3 
 0.002 2020 9, -17, -3 
    
Controls vs. DLBa 0.02 178 -3, -20, -2 
 0.04 152 -7, -7, 13 
 0.03 138 -20, -24, -1 
 0.04 78 -16, -14, 3 
    
 0.02 235 10, -17, 17 
 0.01 228 5, -20, -2 
 0.02 134 18, -14, 4 
 0.04 17 23, -27, 3 
    
Controls vs. DLBd 0.006 1726 -2, -4, 1 
 0.004 2092 5, -22, -1 
    
DLB vs. CRTSD 0.02 185 -16, -13, 5 
 0.03 84 -10, -34, 7 
 
0.03 24 -4, -23, -1 
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Table 3 Demographic and group characteristics of DLB subgroups based on survival data. 
 
Values expressed as Mean ± 1 SD. 
 
RVH = Recurrent visual hallucinations, CF = Cognitive fluctuation, RBD = REM sleep behaviour disorder, 
DaTSCAN = Dopaminergic SPECT imaging, IHD = Ischaemic heart disease, T2DM = Type 2 diabetes mellitus, 
No. of medications = Index of medical comorbidity. 
 
†Performed on transformed data.  
‡Individuals with DaTSCAN imaging were all rated as ‘positive’. 
*
 Total (right + left) expressed as % of total intracranial volume. 
Bold text denotes statistical significance. 
 
 
 
 
DLBa 
 
DLBd 
 
Statistic, p value 
    
n 26 9  
Gender (m: f) 19: 7 8: 1 χ2 = 0.9, 0.3 
Age (yrs.) 78.3 ± 7.5 78.6 ± 5.2 t33 = 0.2, 0.9 
MMSE 19.9 ± 5.7 21.7 ± 3.8 t33 = 0.9, 0.4 
CAMCOG 66.2 ± 16.2 72.1 ± 11.7 t33 = 1.0, 0.3 
NPI total 20.2 ± 15.6 25.4 ± 21.9 U35 = 109.5, 0.7 
Bristol ADL 17.9 ± 9.8 19.0 ± 9.2 t33 = 0.3, 0.8 
SRTmean 683.5 ± 547.3 716.8 ± 739.3 t33 = 0.2, 0.9† 
SRTSD 261.6 ± 365.3 439.8 ± 954.0 t33 = 0.03, 1.0† 
CRTmean 1065.9 ± 672.0 1211.7 ± 934.7 t33 = 0.9, 0.4† 
CRTSD 410.4 ± 512.9 662.3 ± 992.0 t33 = 1.3, 0.2† 
Digit_Vigmean 577.2 ± 113.5 677.5 ± 62.1 t33 = 3.5, 0.002† 
Digit_VigSD 118.7 ± 42.6 165.9 ± 43.1 t33 = 2.8, 0.01† 
Duration of illness (months) 42.0 ± 19.1 36.8 ± 25.4 t33 = 0.6, 0.5 
    
ChI use (y: n) 22: 4 8: 1 χ2 = 0.1, 0.8 
RVH (% yes) 81 (21/26) 89(8/9) χ2 = 0.3, 0.6 
CF (% yes) 92 (24/26) 89 (8/9) χ2 = 0.1, 08 
RBD (% yes) 69 (18/26) 33 (3/9) χ2 = 3.6, 0.06 
UPDRS III 27.0 ± 10.4 22.9 ± 11.6 t33 = 1.0, 0.3 
DaTSCAN‡ (yes: no) 19: 7 3: 6  
    
History of: 
 
   
IHD (% yes) 27 (7/26) 11 (1/9) χ2
 
= 0.9, 0.3 
T2DM (% yes) 12 (3/26) 11 (1/9) χ2
 
= 0.001, 1.0 
Hypertension (% yes) 31 (8/26) 33 (3/9) χ2
 
= 0.20, 0.9 
Hypercholesterolemia (% yes) 38 (10/26) 11 (1/9) χ2
 
= 2.3, 0.1 
Atrial Fibrillation (% yes) 8 (2/26) 0 (0/9) χ2 
 
= 0.7, 0.4 
No. of medications    
5 or less 11 6  
More than 5 15 3  
    
Total hippocampal volume* 0.30 ± 0.06 0.27 ± 0.06 t33 = 1.3, 0.2 
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Highlights 
 
• Thalamic atrophy relate to attentional dysfunction and fluctuations in DLB.  
• Atrophy pattern differed in patients who died within 12 months of assessment. 
• Results characterise changes underpinning disease symptoms and heterogeneity. 
